HOME >> MEDICINE >> NEWS
New drug protects against the hardening of arteries

Atherosclerosis, a leading cause of morbidity and mortality in Western nations, is caused by the accumulation of cholesterol-rich lipoproteins that adhere to vessel walls and develop into macrophages. These macrophages, laden with lipid, cause inflammation in the vessel and, over time, formation of a lesion. A family of proteins known as PPARs (PPARalpha, PPARbeta, and PPARgamma) are expressed by cells of the artery wall and drugs that activate PPARalpha and PPARgamma (known as PPAR agonists) are used to treat high lipid levels (such as cholesterol and triglycerides), and type 2 diabetes, respectively. The presence of PPARs in the vessel wall has prompted researchers to investigate the effects of PPAR agonists on atherosclerosis in mice. While studies have shown that PPARgamma agonists are beneficial in the treatment of atherosclerosis in mice, the role of other members of this protein family have remained unclear.

In the December 1 issue of the Journal of Clinical Investigation, Andrew Li and colleagues from the University of California, San Diego compare the effects of PPARalpha, PPARbeta, and PPARgamma agonists on the development of atherosclerosis in a mouse model of this disease. They observed profound protective effects of the PPARalpha agonist GW7647, comparable to the PPARgamma agonist rosiglitazone that is currently used to treat type 2 diabetes. GW7647 also reduced weight gain, and insulin and lipoprotein levels. In contrast, lesion development was not inhibited by a PPARbeta agonist.

In an accompanying commentary, Peter Tontonoz and Antonio Castrillo from the University of California, Los Angeles discuss the mechanism described by Li and colleagues by which lipid accumulation is reduced by these agonists, thereby giving us a greater understanding of the roles of PPAR family members in atherosclerosis. Most importantly, the study highlights that the use of a drug (or drugs) that target multiple PPARs, particularly PPARalpha and PPARgamma,
'"/>

Contact: Brooke Grindlinger
press_releases@the-jci.org
212-342-0497
Journal of Clinical Investigation
1-Dec-2004


Page: 1 2

Related medicine news :

1. Red wine protects the heart
2. Component of green tea protects injured livers in mice
3. Substance protects resilient staph bacteria
4. Gene vaccine protects mice against development of Her2/neu breast cancer
5. Blocking molecules protects health of implants
6. Good parenting protects against chronic illness says professor of public health
7. Exercising limbs protects brain cells affected by Parkinsons, study in rodents shows
8. Mechanism found that protects aggressive melanoma from angiogenesis inhibitors
9. Chicken pox vaccine saves $$, protects whole population
10. Diet of worms protects against bowel cancer
11. NIAID vaccine protects against SARS virus infection in mice

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2016)... IN (PRWEB) , ... February 10, 2016 , ... ... benefits advisory organization, welcomes S.S. Nesbitt as the latest addition to its growing ... has seven other locations throughout the Southeast, from Orlando to Huntsville and in ...
(Date:2/10/2016)... ... ... Armune BioScience signed a definitive agreement with ARCpoint Labs ... the country. Launched in April of 2015, Apifiny is the only cancer specific, non-PSA ... volume exceeded 3,000 tests in 2015. Primary care physicians and urologists have utilized Apifiny ...
(Date:2/10/2016)... ... February 10, 2016 , ... For additional information contact ... , Pioneering book "Better with Age: The Ultimate Guide to Brain Training" by award-winning ... improve memory. The book’s publication date is March 16, 2016. A free review ...
(Date:2/10/2016)... ... February 10, 2016 , ... Everseat has joined the award-winning ... to physicians. The integration will enable Allscripts users to post open appointments to ... mobile app. , The partnership gives Everseat substantial added power to help Allscripts ...
(Date:2/10/2016)... ... ... Workrite Ergonomics this week announced the launch of the Conform Monitor Arm Series, ... was to develop a product from the ground up that would provide the most ... Hulsey, Product Manager for Workrite Ergonomics. “The Conform series features a wide variety ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... BASEL, Switzerland and SAN DIEGO ... Houston , Inc., a global leader in viral gene ... gene therapy treatments for congestive heart failure and other ... to develop a scalable manufacturing process and produce cGMP-grade ... clinical trials. --> ...
(Date:2/10/2016)... Immune Pharmaceuticals Inc. (NASDAQ: IMNP ), ... has filed a patent application directed to the treatment ... --> --> The new invention ... (histamine dihydrochloride) in combination with immune checkpoint inhibitors. The ... of Ceplene and IL-2 therapy in patients with Acute ...
(Date:2/10/2016)... ANGELES , Feb. 10, 2016  Oxis International ... cancer drug, OXS-1550, was described as a "clinical trial ... the drug went into complete cancer remission. ... University of Minnesota Masonic Cancer Center. --> ... University of Minnesota Masonic Cancer Center. --> ...
Breaking Medicine Technology:
Cached News: